Compare Cintas Corporation (CTAS) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Revvity Inc — how do they compare? Cintas Corporation trades at $204.11 (market cap $82.15B), while Revvity Inc trades at $116.47 (market cap $12.91B). The key difference: Cintas Corporation is far larger — about 6.4× Revvity Inc's market cap, and Cintas Corporation pays the higher dividend (1.01%). Which is the better fit depends on your goals.
| CTAS | RVTY | |
|---|---|---|
Market Cap | $82.15B | $12.91B |
Sector | Industrials | Technology |
52-Week High | $225.10 | $117.75 |
52-Week Low | $163.55 | $82.26 |
Enterprise Value | $84.56B | $15.23B |
Dividend Yield | 1.01% | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $204.86, up 1.06% on the day, with a bullish technical signal and recent earnings beats driving positive momentum. The company reported strong Q2 2026 EPS of $1.29, exceeding expectations, and maintains robust fundamentals with a 17.75% net income margin and 40.59% ROE. Revenue growth is steady, reaching $10.34B in 2025, supported by consistent profitability and a dividend payout.
The outlook is positive, with a consensus price target of $225.83 implying ~10% upside, though high valuation ratios (P/E 41.81) and competitive pressures pose risks. Institutional interest is strong, with recent upgrades, but investors should monitor debt levels and economic sensitivity.
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
